English (UK)French

ACC BioTech


ACC International Holdings, through its Biotech subsidiary (ACCBT), is a controlling shareholder of Brainstorm Cell Therapeutics Inc (OTC.QB: BCLI), a leading developer of innovative, autologous adult stem cell therapies, for neurodegenerative diseases. BrainStorm's proprietary technology (NurOwn™) is in the late stages of development, and may use for treating severe and incurable disorders, such as Amyotrophic Lateral Sclerosis (ALS - also known in the US as Lou Gehrig's disease), Multiple Sclerosis (MS) Parkinson’s Disease (PD), and more.

BrainStorm is currently conducting a Phase IIa ALS clinical trial at the Hadassah University Medical Center in Jerusalem. The company is also scheduled to commence a Phase II clinical trial in the USA during 2013, pending FDA approval.